To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD).
Methods:
Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses.
Results:
Four RCTs were included, with a total of 649 and 621 eyes in the T&E and fixed regimen cohort at 12 months, and 267 and 249 eyes at 24 months. Pooled analysis of mean BCVA change included all four RCTs at 12 months and two RCTs at 24 months, showing no difference between the two groups (12-month: SMD = 0.08, 95% CI: −0.20 to 0.35, p = 0.55; 24-month: SMD = 0.04, 95% CI: −0.13 to 0.21, p = 0.64). Pooled analysis of OCT CRT change at 12 months included three studies, showing no difference between the two groups (SMD = 0.03, 95% CI: −0.46 to 0.51, p = 0.91). Pooled analysis of mean injection number included all four RCTs at 12 months and two RCTs at 24 months, showing significant difference between the two groups (12-month: SMD = −1.11, 95% CI: −1.67 to −0.56, p < 0.001; 24-month: SMD = −1.34, 95% CI: −1.54 to −1.15, p < 0.001).
Conclusion:
A T&E regimen proved as effective as a fixed dosage regimen throughout a 24-month follow-up and with a lower number of injections.
BrownDMKaiserPKMichelsM, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med2006; 355(14): 1432–1444.
2.
RosenfeldPJBrownDMHeierJS, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med2006; 355(14): 1419–1431.
3.
Chin-YeeDEckTFowlerS, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol2016; 100(7): 914–917.
4.
HanemotoTHikichiYKikuchiN, et al. The impact of different antivascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLoS ONE2017; 12(12): e0189035.
5.
FungAELalwaniGARosenfeldPJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol2007; 143: 566–583.
6.
HolzFGAmoakuWDonateJ, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology2011; 118: 663–671.
7.
ChakravarthyUHardingSPRogersCA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet2013; 382(9900): 1258–1267.
8.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology2014; 121(5): 1092–1101.
9.
SpaideR.Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol2007; 143: 679–680.
10.
Chin-YeeDEckTFowlerS, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol2016; 100(7): 914–917.
11.
RufaiSRAlmuhtasebHPaulRM, et al. A systematic review to assess the ‘/treat-and-extend/’ dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye2017; 31(9): 1337–1344.
12.
KimLNMehtaHBarthelmesD, et al. Meta-analysis of real world outcomes of intravitreal ranibizumab for the treatment of neovascular age related macular degeneration. Retina2016; 36: 1418–1431.
13.
OkadaMKandasamyRChongEW, et al. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol2018; 192: 184–197.
14.
GilliesMCWaltonRJArnoldJJ, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology2014; 121(3): 676–681.
15.
American Society of Retina Specialists. Annual preferences and trends survey, 2014, http://www.asrs.org
16.
KertesPJGalicIJGreveM, et al. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology2019; 126(6): 841–848.
17.
KertesPJGalicIJGreveM, et al. Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol2020; 138: 244–250.
18.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med2009; 6: e1000100.
19.
HigginsJPTDeeksJJAltmanDG.Special topics in statistics. In: HigginsJPTGreenS (eds) Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. https://handbook-5-1.cochrane.org/index.htm#front_page.htm (accessed 29 April 2019).
20.
HigginsJPTAltmanDGSterneJAC, et al. Assessing risk of bias in included studies. In: HigginsJPTGreenSChandlerJ, et al. (eds) Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration, 2011. https://handbook-5-1.cochrane.org/index.htm#front_page.htm (accessed 29 April 2019).
HigginsJPGreenS (eds). Cochrane handbook for systematic reviews of interventions (Vol. 4). John Wiley & Sons, 2011.
23.
EggerMDavey SmithGSchneiderM, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ1997; 315(7109): 629–634.
24.
HagaAKawajiTIdetaR, et al. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration. Acta Ophthalmol2018: 96: e393–e398.
25.
SilvaRBertaALarsenM, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology2018; 125(1): 57–65.
26.
WykoffCCCroftDEBrownDM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology2015; 122(12): 2514–2522.
27.
WykoffCCOuWCBrownDM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina2017; 1(4): 314–321.
28.
WykoffCCOuWCCroftDE, et al. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol2018; 102(4): 460–464.
29.
GaleRPMahmoodSDevonportH, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond)2019; 33(Suppl 1): 1–21.
30.
PatelPJDevonportHSivaprasadS, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol2017; 11: 1957–1966.
31.
AmoakuWBlakeneySFreemanM, et al. Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye (Lond)2012; 26(Suppl 1): S2–21.
32.
BhandariSNguyenVArnoldJ, et al. Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: data from the fight retinal blindness! registry. Ophthalmology2019; 127: 369–376.
33.
ArnoldJJCampainABarthelmesD, et al. Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology2015; 122(6): 1212–1219.
34.
FingerRPWiedemannPBlumhagenF, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol2013; 91(6): 540–546.
35.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, MartinDFMaguireMG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology2012; 119(7): 1388–1398.
36.
RufaiSRAlmuhtasebHPaulRM, et al. A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye (Lond)2017; 31(9): 1337–1344.
37.
MenonGChandranMSivaprasadS, et al. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc trial). Eye (Lond)2013; 27(8): 959–963.
38.
AriasLCaminalJMCasasL, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol2008; 92: 1636–1641.
39.
GuptaBAdewoyinTPatelSK, et al. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol2011; 95(3): 386–390.
40.
ReibaldiMAvitabileTBandelloF, et al. The effectiveness of 0.6% povidone iodine eye drops in reducing the conjunctival bacterial load and needle contamination in patients undergoing anti-VEGF intravitreal injection: a prospective, randomized study. J Clin Med2019; 8(7): 1031.
41.
ReibaldiMFallicoMAvitabileT, et al. Risk of death associated with intravitreal anti-vascular endothelial growth factor therapy: a systematic review and meta-analysis. JAMA Ophthalmol2019; 138: 50–57.
42.
FallicoMLoteryAJLongoA, et al. Risk of acute stroke in patients with retinal artery occlusion: a systematic review and meta-analysis. Eye (Lond)2020; 34(4): 683–689.
43.
FallicoMRussoALongoA, et al. Internal limiting membrane peeling versus no peeling during primary vitrectomy for rhegmatogenous retinal detachment: a systematic review and meta-analysis. PLoS ONE2018; 13(7): e0201010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
